CPRX Stock Summary and Trading Ideas (Catalyst Pharmaceuticals | NASDAQ:CPRX)

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

What symbol and exchange does Catalyst Pharmaceuticals shares trade?

Catalyst Pharmaceuticals trades on the NASDAQ stock market under the symbol CPRX.

What is Catalyst Pharmaceuticals stock price doing today?

As of April 1, 2026, CPRX stock price climbed to $24.82 with 1,288,418 million shares trading.

What is Catalyst Pharmaceuticals's Beta?

CPRX has a beta of 0.34, meaning it tends to be less sensitive to market movements. CPRX has a correlation of 0.05 to the broad based SPY ETF.

How much is Catalyst Pharmaceuticals worth?

CPRX has a market cap of $3.05 billion. This is considered a Mid Cap stock.

How much money does Catalyst Pharmaceuticals make?

Last quarter Catalyst Pharmaceuticals reported $153 million in Revenue and $.68 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.19.

What is the highest and lowest price Catalyst Pharmaceuticals traded in the last 3 year period?

In the last 3 years, CPRX traded as high as $26.58 and as low as $11.09.

What are the top ETFs holding Catalyst Pharmaceuticals?

The top ETF exchange traded funds that CPRX belongs to (by Net Assets): IJR, VTI, AVUV, IWM, XBI.

Is Catalyst Pharmaceuticals (CPRX) a good investment?

CPRX has underperformed the market in the last year with a return of +2.4%, while SPY returned +18.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CPRX shares. However, CPRX has outperformed the market in the last 3 month and 2 week periods, returning +6.3% and +6.4%, while SPY returned -3.6% and -2.1%, respectively. This indicates CPRX has been having a stronger performance recently.

What are the support and resistance levels for Catalyst Pharmaceuticals (CPRX)?

CPRX support price is $24.22 and resistance is $25.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPRX shares will trade within this expected range on the day.